LeonaBio (LONA) Shares Plunge -55% on Warrant Exercise Overhang
Key Takeaways
- LeonaBio (LONA) shares fell roughly 55% over the past 30 days, from about $7.83 to approximately $3.52, as a warrant-exercise overhang triggered heavy selling.
- The sharpest decline followed the company's September 25 announcement opening an exercise window for Series A warrants covering about 23 million shares at $6.35 per share.
- The dilution risk outweighed otherwise steady clinical progress on the Phase 3 ELAINE-3 trial of lasofoxifene in ESR1-mutated metastatic breast cancer.
- LeonaBio remains pre-revenue and cash-burning, ending the second quarter with $51.1 million in cash and investments.
- Analyst ratings remain broadly positive, with price targets well above the current trading level, but the market is repricing the stock for near-term share issuance.
LeonaBio (LONA) Company Background
LeonaBio, Inc. is a clinical-stage biopharmaceutical company headquartered in the Seattle, Washington area that develops novel small-molecule therapies for diseases with high unmet medical need. The company was formerly known as Athira Pharma and changed its name to LeonaBio in January 2026 after acquiring global rights to its lead oncology asset.
Its lead drug candidate, lasofoxifene, is a next-generation selective estrogen receptor modulator (SERM) being evaluated in the Phase 3 ELAINE-3 trial in combination with abemaciclib for estrogen receptor-positive, HER2-negative, ESR1-mutated metastatic breast cancer. The company's second candidate, brelgometon (formerly ATH-1105), is an orally available therapy in development for amyotrophic lateral sclerosis (ALS).
Investors follow LONA primarily for its oncology pipeline, given the potentially large addressable market for ESR1-mutated breast cancer, a genetically defined population with limited treatment options after disease progression. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
LeonaBio (LONA) Recent Stock Performance
Over the last 30 days, LONA has fallen approximately 55%, declining from a closing price near $7.83 to around $3.52. The stock had traded in a range of roughly $6 to $9 through much of August before breaking down decisively in late September, when it lost more than 15% on September 24, about 35% on September 25, and a further double-digit decline on September 28.
The quarterly trend is similarly negative. From a level near $9.19 at the end of June, shares have dropped more than 60%, reflecting a sustained repricing that accelerated sharply in the final weeks of the quarter. The selloff pushed LONA well below its 50-day and 200-day moving averages and toward the lower end of its 52-week range.
Factors Behind the Last 30 Days of Selling
The dominant catalyst behind the recent decline was the company's decision to open a warrant exercise window. On September 25, LeonaBio initiated an exercise period for Series A warrants covering approximately 23 million common shares at an exercise price of $6.35 per share, running through October 19, 2026. The move could generate up to roughly $146 million in gross proceeds but also introduced a meaningful prospective share-issuance overhang, prompting investors to reprice the stock sharply lower.
This dilution concern overshadowed otherwise encouraging clinical updates. During the period, LeonaBio reported that its Phase 3 ELAINE-3 trial had enrolled 495 patients and remained on track to complete enrollment of approximately 600 participants in the fourth quarter of 2026. The company also disclosed second-quarter results showing a narrower-than-expected loss of $0.80 per share versus a consensus estimate of $1.12.
On the analyst front, Piper Sandler reiterated an Overweight rating with a $20 price target, while Mizuho maintained an Outperform rating with a $15 target. These positive views did not prevent the selloff, as near-term financing dynamics took precedence over longer-term pipeline potential.
Drivers of Performance Over the Quarter
The broader multi-month decline reflects a combination of structural factors. As a pre-revenue clinical-stage company, LeonaBio generates no product revenue and relies on financing to fund development. In December 2025, the company completed a $90 million private placement alongside its lasofoxifene license agreement, with warrants exercisable for up to an additional $146 million. The eventual exercise of those warrants was always a potential source of dilution, and the September opening of the exercise window brought that overhang into focus.
At the same time, rising research and development spending tied to the ELAINE-3 trial has increased cash burn. The company ended June 2026 with $51.1 million in cash, cash equivalents, and investments, down from $88.3 million at the end of 2025. Against this backdrop, shares declined steadily through the quarter even as clinical milestones remained on schedule.
What to Watch Going Forward
The most important near-term factor is the outcome of the warrant exercise window, which closes October 19, 2026. The number of shares ultimately issued and the resulting capital raised will shape both the company's balance sheet and its share count.
Looking further ahead, investors will monitor completion of enrollment in the Phase 3 ELAINE-3 trial, expected in the fourth quarter of 2026, followed by topline data anticipated in the second half of 2027. Additional catalysts include updates on the brelgometon ALS program, quarterly cash-burn trends, and any changes in analyst ratings or price targets. As with all clinical-stage biotechs, trial outcomes and regulatory developments remain the central drivers of long-term value. From what I see, keeping an eye on these milestones will be key.
Tracking Market Moves with AI Assistance
In my own analysis, I frequently review Tickeron’s AI Trading Bots to get a sense of how automated strategies are positioned around names like LONA. These tools scan thousands of tickers and highlight top-performing approaches across different timeframes and styles, which can be a helpful complement when sorting through volatility in clinical-stage names. It gives a quick view of momentum signals without replacing fundamental work.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.
LONA sees its Stochastic Oscillator ascends from oversold territory
On October 01, 2026, the Stochastic Oscillator for LONA moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 64 instances where the indicator left the oversold zone. In 57 of the 64 cases the stock moved higher in the following days. This puts the odds of a move higher at over 89%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where LONA's RSI Indicator exited the oversold zone, 29 of 34 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 85%.
Following a +27.40% 3-day Advance, the price is estimated to grow further. Considering data from situations where LONA advanced for three days, in 220 of 265 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
LONA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on September 09, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on LONA as a result. In 72 of 83 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 87%.
The Moving Average Convergence Divergence Histogram (MACD) for LONA turned negative on September 09, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 40 similar instances when the indicator turned negative. In 32 of the 40 cases the stock turned lower in the days that followed. This puts the odds of success at 80%.
LONA moved below its 50-day moving average on September 09, 2026 date and that indicates a change from an upward trend to a downward trend.
The 50-day moving average for LONA moved below the 200-day moving average on September 21, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where LONA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
The Aroon Indicator for LONA entered a downward trend on October 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 11 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.805) is normal, around the industry mean (26.780). P/E Ratio (0.000) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating steady price growth. LONA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LONA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement